Therapeutic Group: Rheumatoid arthritis Presentation Baricentâ„¢ 4: Each film coated tablet contains Baricitinib INN 4 mg Description Baricitinib is a selective and reversible inhibitor of Janus kinase JAK1 and JAK2. In isolated enzyme assays, baricitinib inhibited the activities of JAK1, JAK2, Tyrosine Kinase 2 and JAK3 with IC50 values of 5.9, 5.7, 53 and > […]
Therapeutic Group: Rheumatoid arthritis Presentation Baricentâ„¢ 2: Each film coated tablet contains Baricitinib INN 2 mg Description Baricitinib is a selective and reversible inhibitor of Janus kinase JAK1 and JAK2. In isolated enzyme assays, baricitinib inhibited the activities of JAK1, JAK2, Tyrosine Kinase 2 and JAK3 with IC50 values of 5.9, 5.7, 53 and > […]
Description Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis and psoriatic arthritis. Tofacitinib inhibits JAK dependent cytokinesignaling. JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane. JAKsphosphorylate and activate Signal Transducers and Activators of Transcription(STATs) which modulate intracellular activity including […]
Description Deflazacort provides anti-inflammatory action by inhibiting Phospholipase A2 enzymeWhich is responsible for prostaglandin synthesis. Besides Deflazacort decreases the release of certain chemicals that are important in the immune system. By decreasing the release of these chemicals Deflazacort provides immunosuppressive action. Presentation Flacort Tablet: Each tablet contains Deflazacort INN 6 mg.Flacort 24 Tablet: Each tablet contains Deflazacort […]